

Thursday, November 6

■ Session Language : Mixed Japanese and English
■ Session Language : English

		8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00		
Tokyo International Forum	Room 1 4F C Block Hall C	8:50~9:00 Opening Remarks	9:00~10:30 Symposium 1 Neo-ADAURA, ADAURA vs. LAURA in Marginally resectable NSCLC with EGFR mt.		10:40~12:10 Symposium 2 Exploration of Cancer Molecular Targeted Drug Resistance Mechanisms and Methods for Overcoming Them		12:30~13:20 Luncheon Seminar 1 Optimal First-line Treatment and Man- agement for EGFR Mutant NSCLC	13:30~14:00 Board Chair- man's Lecture	14:05~16:05 Chairman's Program 1 Meet the Experts		16:20~17:10 Invited Lecture 1 Speaker : Charles Swanton				
	Room 2 7F B Block Hall B7 (1)		9:00~9:30 Educatio- nal Lecture 1	9:30~10:00 Educatio- nal Lecture 2	10:00~10:30 Educatio- nal Lecture 3	10:40~11:10 Educatio- nal Lecture 4	11:10~11:40 Educatio- nal Lecture 5	11:40~12:10 Educatio- nal Lecture 6	12:30~13:20 Luncheon Seminar 2	14:05~15:35 Sponsored Symposium 2 Treatment Direction for Driver gene Mutated NSCLC ~Overview of the Latest Treatments from the Perioperative Stage to Advanced and Recurrent Disease!~		15:40~17:10 Biomarker Committee Program Current Status and Challenges of Biomarkers in Immunotherapy : Marking 10 Years Since Approval of Immune Checkpoint Inhibitors in Japan		17:30~18:20 Evening Seminar 1	
	Room 3 7F B Block Hall B7 (2)		9:00~10:30 JLCS-IASLC Joint Symposium Perioperative Treatments Chairs : Karen Kelly Nobuyuki Yamamoto		10:40~12:10 Symposium 3 Treatment of EGFR Gene-Positive Advanced Non-Small Cell Lung Cancer		12:30~13:20 Luncheon Seminar 3 Perioperative Treat- ment in NSCLC : Insights from Recent Randomized Trials		14:05~15:35 Symposium 4 Palliative Care and Advance Care Planning in Lung Cancer Diagnosis and Treatment		15:40~17:20 Joint Session : Early Career Support Committee/International Committee Chairs : Kazuyoshi Imaizumi Makoto Nishio				
	Room 4 5F B Block Hall B5 (1)		9:00~10:00 Abstract Oral 1 Interstitial Pneumonia & Other Diseases			10:40~12:10 Sponsored Symposium 1 Evolving Lung Cancer Immuno- therapy : Elucidating Non-Response & Resistance Pathogenesis and Pioneering Innovative Approaches		12:30~13:20 Luncheon Seminar 4	14:05~15:35 Workshop 1 Evolution of Personalized Medicine Advanced by Liquid Biopsies		15:40~17:10 Video Session 1 Surgery After Induction Therapy or Salvage Surgery		17:30~18:20 Evening Seminar 2 Perioperative treatment of Non-Small Cell Lung Can- cer - determine indication for Neoadjuvant therapy/ Adjuvant therapy -		
	Room 5 5F B Block Hall B5 (2)		9:00~10:00 Abstract Oral 2 Non-Small Cell Lung Cancer : Locally Advanced (Stage III)	10:05~11:05 Abstract Oral 3 EGFR Gene Mutation-Positive Lung Cancer 1		11:20~12:10 Invited Lecture 2 Speaker : Malcolm V. Brock		12:30~13:20 Luncheon Seminar 5 Tumor Treating Fields Therapy (TTFields Therapy) - A novel option for NSCLC treatment -	14:05~15:35 Symposium : Academic Committee Program 1 Latest Research Methods (Spatial Genomic Analysis, Digital Pathology, Organoids, Mitochondri- al Mutations, Liquid Biopsy, etc.)		15:40~17:10 Workshop 2 Forefront of Mesothelioma Practice : From Diagnosis to Treatment, and New Developments in Basic Research		17:30~18:20 Evening Seminar 3 Challenge to MET exon14 skipping mutation-positive lung cancer		
	Room 6 7F D Block Hall D7		9:00~10:30 Workshop 3 Forefront of Bronchoscopic Specimen Collection and Treatment		10:40~12:10 Early Career Support Committee Program 1 My Career Path : Diverse Relationships Between Career and Medical Departments		12:30~13:20 Luncheon Seminar 6 Tepmetko latest findings -VISION study 3-year follow-up data and tips for edema management-		14:05~15:35 Symposium 5 Deep Discussion Series : Expanding Indications for Segmentectomy in Lung Cancer		15:40~17:10 Workshop 4 Diagnosis and Treatment of Thymic Epithelial Tumors : State of the Art		17:30~18:20 Evening Seminar 4 The Current Landscape of KRAS-Mutant Lung Cancer: Biology-Based Therapeutic Strategy with Lumakras		
	Room 7 5F D Block Hall D5		9:00~10:30 Workshop 5 Development of Therapies for Lung Cancer Using Advanced Bioresources		10:40~12:10 Workshop 6 Utilization of AI Technology in Lung Cancer Practice		12:30~13:20 Luncheon Seminar 7 How to utilize the 2025 edition of the The Japanese Lung Cancer Society Guideline for non- small cell lung cancer?		14:05~15:35 Committee for Database Management Program		15:40~16:40 GL : Palliative Care Subcommittee Program	16:45~17:15 Editorial Commit- tee Program	17:30~18:20 Evening Seminar 5 Targeting 40% EGFR Mutation and 4% ALK Fusion Detection Rates in Lung Adenocarcinoma		
	Room 8 1F D Block Hall D1		9:00~10:00 Abstract Oral 4 Stage IV NSCLC : Palliative Care	10:05~11:05 Abstract Oral 5 Diagnosis 1		11:10~12:10 Abstract Oral 6 Gene Mutation-Positive Lung Cancer (Clinical Trials)		12:30~13:20 Luncheon Seminar 8 Management of Side Effects in Lung Can- cer Pharmacotherapy through Multidisci- plinary Collaboration	14:05~15:05 Abstract Oral 7 Molecular Expression and Its Significance in Thoracic Malignancies		15:10~16:10 Abstract Oral 8 Elderly Patients		16:15~17:15 Abstract Oral 9 Robotic Surgical Techniques		
	Room 9 5F G Block G502		9:00~10:00 Abstract Oral 10 Radiation Therapy	10:05~11:05 Abstract Oral 11 Small Cell Lung Cancer 1		11:10~12:10 Abstract Oral 12 Small Cell Lung Cancer 2		12:30~13:20 Luncheon Seminar 9 Strategies for first-line therapy of ALK-positive NSCLC	14:05~15:05 Abstract Oral 13 Diagnosis 2		15:10~16:10 Abstract Oral 14 Immunotherapy : Clinical Trials		16:15~17:15 Abstract Oral 15 Diagnosis 3		
	Room 10 5F G Block G510		9:00~10:00 Abstract Oral 16 Non-Small Cell Lung Cancer : Locally Advanced 1	10:05~11:05 Abstract Oral 17 Non-Small Cell Lung Cancer : Locally Advanced 2		11:10~12:10 Abstract Oral 18 Surgery and Treatment (for Thymic Tumors) 1		12:30~13:20 Luncheon Seminar 10 Current Status and Chal- lenges of Multiplex Test- ing in Lung Cancer Care : Clinical Perspectives from Japan and Taiwan	14:05~15:05 Abstract Oral 19 Non-Small Cell Lung Cancer : Locally Advanced 3		15:10~16:10 Abstract Oral 20 Non-Small Cell Lung Cancer : Locally Advanced 4		16:15~17:15 Abstract Oral 21 Metastatic Pulmonary Tumors		P14 Pathology 1 P15 Complications P16 Immunotherapy 2 P17 Case Reports (of Thymic Tumors) 2 P18 Surgical Techniques P19 Diagnosis (Pathology and Imaging) (of Thymic Tumors) 2
	Room 11 4F G Block G402	P1 TR 1 P2 Comorbidities P3 Diagnosis (Pathology and Imaging) (of Thymic Tumors) 1 P4 Perioperative and Other Care P5 Case Reports (of Thymic Tumors) 1 P6 Immunotherapy 1 P7 SCLC 1 P8 Gene Mutation-Positive Lung Cancer (Other than EGFR and ALK) 1	9:00~10:00 Abstract Oral 22 Surgery and Treatment (for Thymic Tumors) 2		11:10~12:10 Special Report How Should We Ad- dress Manufacturing Issues Affecting Com- panion Diagnostics?		12:30~13:20 Luncheon Seminar 11	14:20~15:50 Chairman's Program 2 Meet the Foreign Experts Experts : David P. Carbone Heather Wakelee Charles Swanton Malcolm V. Brock Paul Van Schil						P20 ALK and Other Driver Genes P21 SCLC 2 P22 Gene Mutation-Positive Lung Cancer (Other than EGFR and ALK) 2 P23 Case Reports P24 Diagnostics 2 P25 Team Medicine/Nursing/ Rehabilitation : Rehabilitation, Team Medicine and Other Care P26 Immunotherapy : Long-Term Survival, Biomarkers and Other Aspects P27 IP and Other Diseases P28 Diagnostic Imaging	
	PAP 4F G Block G409	P9 Rare Tumors P10 Elderly Patients P11 Diagnostics 1 P12 Immunotherapy : irAE Lung Injury, CRS, and Other Conditions P13 Stage IV NSCLC : EGFR - Cases	9:00~17:30 Patient Advocate Program(PAP)												
	Poster venue B2F Hall E		8:00~9:30 Poster Mounting	9:30~11:10 Poster Viewing		11:10~12:10 Poster Presentation 1		12:10~15:10 Poster Viewing		15:10~16:10 Poster Presentation 2		16:10~17:00 Poster Viewing	17:00~18:00 Poster Removal		

Friday, November 7

■ Session Language : Mixed Japanese and English
■ Session Language : English

		8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00				
Tokyo International Forum	Room 1 4F C Block Hall C		8:30~10:30 Chairman's Program 3 Reconsidering Social Security Through Lung Cancer		10:40~11:30 Invited Lecture 3	12:00~12:50 Luncheon Seminar 12 The Significance of Cancer Genomic Profiling in Lung Cancer	13:00~13:30 Chairman's Lecture	13:35~15:05 Symposium 6 Deep Discussion Series : Is It Possible to Define Resectable Lung Cancer in Locally Advanced Lung Cancer?	15:15~16:45 Symposium 7 Frontiers in Perioperative Treatment of Resectable Non-Small Cell Lung Cancer - Optimization of Immune Checkpoint Inhibitors and Future Prospects Chairs : Kenji Suzuki Kazuhisa Takahashi	16:55~18:25 English Outstanding Session Chairs : Pasi A. Jänne Jacob Sands							
	Room 2 7F B Block Hall B7 (1)		8:30~10:00 Symposium 8 Team-Based Medical Approach to Brain Metastasis Treatment : Aiming for Improved Quality of Life	10:10~11:40 Symposium 9 New Developments in Pathology Pioneering the Future of Lung Cancer Practice		12:00~12:50 Luncheon Seminar 13 A time of transformation: Lung cancer treatment enters a new stage - what is expected of us now?		13:35~14:05 Educational Lecture 7	14:05~14:35 Educational Lecture 8	14:35~15:05 Educational Lecture 9	15:15~15:45 Educational Lecture 10	15:45~16:15 Educational Lecture 11	16:15~16:45 Educational Lecture 12	16:55~17:25 Educational Lecture 13	17:25~17:55 Educational Lecture 14	18:00~18:30 Invited Lecture 4	
	Room 3 7F B Block Hall B7 (2)		8:30~10:00 Symposium 10 Update for Treatment Strategies for Small Cell Lung Cancer Chairs : Makoto Nishio Kayoko Tsujino	10:10~11:40 Workshop 7 Surgery vs Stereotactic Radiotherapy vs Ablation Therapy (RFA, Cryotherapy) for Pulmonary Tumors		12:00~12:50 Luncheon Seminar 14 Treatment Strategies for HER2-Mutated Metastatic Non-Small Cell Lung Cancer and management of adverse events for T-DXd		13:35~15:05 Workshop 8 Development of Treatments Other Than EGFR for NSCLC with Driver Gene Mutations	15:10~16:40 Symposium 11 Current Status of Antibody-Drug Conjugate (ADC) Development in Lung Cancer Chairs : Hidetoshi Hayashi Koichi Goto	16:50~17:40 Invited Lecture 5	17:45~18:35 Invited Lecture 6 Speaker : David Lam						
	Room 4 5F B Block Hall B5 (1)	7:40~8:20 Morning Seminar 1 Considering the role of lenvatinib in the treatment of thymic carcinoma and aiming to further improve prognosis	8:30~10:00 Workshop 9 Treatment Strategies for Non-Small Cell Lung Cancer with Oligometastases	10:10~11:40 Sponsored Symposium 3 ADC in lung cancer treatment : Clinical features including ILD		12:00~12:50 Luncheon Seminar 15 Optimizing overall survival in ALK+ NSCLC~Lorlatinib : Update analysis from the CROWN study~		13:35~14:35 Abstract Oral 23 Non-Small Cell Lung Cancer : Oligorecurrence and Salvage	14:30~15:40 Sweets Seminar 1 Biomarker Testing in Lung Cancer : Current Status and Challenges	15:50~16:50 Abstract Oral 24 Surgical Techniques	17:00~17:50 Evening Seminar 6 Precision in the Periphery: A New Era of Lung Cancer Diagnosis and Staging with Thin Convex Probe EBUS						
	Room 5 5F B Block Hall B5 (2)	7:40~8:20 Morning Seminar 2 Reconsidering Optimal Treatment for Elderly NSCLC	8:30~10:00 Work-Life Balance Support : Committee for Education and Training Program Deep Discussion : The 'Ideal' and 'Reality' of Supporting the Balancing of Work and Treatment ~Ensuring Cancer Measures That Leave No One Behind and Don't End as Empty Promises~	10:10~11:40 Committee for Lung Cancer Screening Program With Release of the 2025 Evidence-Based Lung Cancer Screening Guidelines, How Will Lung Cancer Screening Change?		12:00~12:50 Luncheon Seminar 16 The forefront of lung cancer treatment ~From trusted testing to the next challenge~		13:35~14:35 Abstract Oral 25 Molecular Targeted Therapy	14:30~15:40 Sweets Seminar 2	15:50~17:50 Joint Session : Pathology Committee/ Criteria for Cytological Diagnosis							
	Room 6 7F D Block Hall D7	7:40~8:20 Morning Seminar 3	8:30~10:00 Video Session 2 Seven Variations of Thoracotomy	10:10~11:40 TNM Classification Committee Program Thoracic Malignancies : Current Status and Future of the 9th Edition TNM Classification		12:00~12:50 Luncheon Seminar 17 How Should We Consider Evolving Treatment Options for Stage IV Non-Small Cell Lung Cancer?		13:40~14:30 Sweets Seminar 3 Pathology-Clinical Collaboration Empowered by Digital Pathology	14:40~15:40 Abstract Oral 26 Second-Line and Other Treatments	15:50~16:50 Committee for Anti-Smoking Promotion Program Smoking Cessation Workshop	17:00~17:50 Evening Seminar 7 Development of HER2-Targeting Treatments in NSCLC : The Past and Emerging Therapies						
	Room 7 5F D Block Hall D5	7:40~8:20 Morning Seminar 4	8:30~10:00 Medical Staff Symposium : Membership Committee Program 1 Genome	10:10~11:40 Medical Staff Symposium : Membership Committee Program 2 Virtual Cancer Board		12:00~12:50 Luncheon Seminar 18 Personalized Treatment Approaches : From Clinical Practice to Statistical Analysis		13:35~14:35 Abstract Oral 27 Diagnostic Imaging	14:30~15:40 Sweets Seminar 4	15:50~16:50 Abstract Oral 28 Driver and Other Genes	16:55~18:25 SDM : Committee for Education and Training Program Practical and Useful 'Shared Decision Making' ~Learning Meaningful Communication Skills Applicable in Clinical Practice~						
	Room 8 1F D Block Hall D1		8:30~9:30 Abstract Oral 29 Immunotherapy 1	9:35~10:35 Abstract Oral 30 Immunotherapy 2	10:40~11:40 Abstract Oral 31 Pleural Mesothelioma		12:00~12:50 Luncheon Seminar 19 Considering the option of "surgery" - The possibility of extended surgery after high-dose irradiation		13:35~14:35 Abstract Oral 32 Small Cell Lung Cancer 3	14:40~15:40 Abstract Oral 33 Small Cell Lung Cancer 4	15:45~16:45 Abstract Oral 34 ICI 1	16:50~17:50 Abstract Oral 35 ICI 2					
	Room 9 5F G Block G502		8:30~9:30 Abstract Oral 36 Pathology and Translational Research	9:35~10:35 Abstract Oral 37 Other Treatments (for Thymic Tumors)	10:40~11:40 Abstract Oral 38 Other Techniques : Prognostic Factors and Pathology		12:00~12:50 Luncheon Seminar 20 Drug Therapy Update for Non-small Cell Lung Cancer		13:35~14:35 Abstract Oral 39 Overcoming Resistance and the Development of Novel Treatments in Lung Cancer Therapy	14:40~15:40 Abstract Oral 40 High-Risk Cases	15:45~16:45 Abstract Oral 41 Perioperative	16:50~18:20 Video Session 3 Surgical Innovations 1					
	Room 10 5F G Block G510		8:30~9:30 Abstract Oral 42 Surgical Innovations	9:35~10:35 Abstract Oral 43 Others Techniques : Surgical Approaches	10:40~11:40 Abstract Oral 44 Treatment Outcomes (Early-Stage Lung Cancer)		12:00~12:50 Luncheon Seminar 21 Nontuberculous Mycobacterial Lung Disease and Lung Cancer		13:35~14:35 Abstract Oral 45 English Session 1 Driver Mutant Lung Cancer 1 Chairs : Tomoya Kawaguchi Pasi A. Jänne	14:40~15:40 Abstract Oral 46 English Session 2 Translational Research 1 Chairs : Shinji Sasada Ross Soo	15:45~16:45 Abstract Oral 47 English Session 3 Driver Mutant Lung Cancer and SCLC Chairs : Satoshi Konno Tiziana Leal						
	Room 11 4F G Block G402	P30 Pathology 2 P31 Locally Advanced 1 P32 Non-Small Cell Lung Cancer : Oligorecurrence and Salvage 1 P33 Molecular Targeted Therapy P34 Pathological Diagnosis (of Thymic Tumors) 1 P35 Metastatic Pulmonary Tumors 1 P36 SCLC 3 P37 Gene Mutation-Positive Lung Cancer (EGFR and ALK) 1	P38 Gene Mutation-Positive Lung Cancer (Other than EGFR and ALK) 3 P39 Diagnostics 3 P40 Driver-Positive Lung Cancer P41 Immunotherapy : Investigation of irAE P42 ICI 1 P43 MPM 1 P44 Radiation Therapy					13:35~14:35 Abstract Oral 48 Immunotherapy : Biomarkers 1	14:40~15:40 Abstract Oral 49 Genomic Diagnosis and CGP 1								
	PAP 4F G Block G409		9:00~17:30					Patient Advocate Program (PAP)									
Poster venue B2F Hall E		8:00~9:30 Poster Mounting	9:30~10:40 Poster Viewing	10:40~11:40 Poster Presentation 3 P29 Translational Research Chair : Ken Tajima	11:40~14:40		Poster Viewing			14:40~15:40 Poster Presentation 4	15:40~16:40 Poster Removal					18:45~20:45 Social Gathering	

- P45 TR 2
- P46 Surgical Techniques (for Thymic Tumors) 1
- P47 Non-Small Cell Lung Cancer : Oligorecurrence and Salvage 2
- P48 Pathological Diagnosis (of Thymic Tumors) 2
- P49 Locally Advanced 3
- P50 Metastatic Pulmonary Tumors 2
- P51 ICI Case Reports
- P52 Diagnostics 4
- P53 Immunotherapy : irAE and Other Adverse Events
- P54 ICI 2
- P55 MPM 2
- P56 SCLC 4
- P57 Gene Mutation-Positive Lung Cancer (EGFR and ALK) 2

Saturday, November 8

Session Language : English

		8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00
Tokyo International Forum	Room 1 4F C Block Hall C		8:30~10:00 Symposium 12 Forefront and Future Vision of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer	10:05~10:55 Invited Lecture 7 Speaker : Chang Hyun Kang	11:00~11:50 Special Lecture	12:00~12:50 Luncheon Seminar 22	13:00~13:50 Invited Lecture 8 Speaker : David P. Carbone	13:55~15:25 Chairman's Program 4 Are Companion Diagnostics Suitable for This Era? ~Light and Shadow of Companion Diagnostics~	15:30~16:10 Shinoi-Kawai Award Commemorative Lecture	16:10~16:20 Closing Remarks			
	Room 2 7F B Block Hall B7 (1)		8:30~10:00 Symposium 13 Development of Treatments for Unresectable Stage III Non-Small Cell Lung Cancer	10:10~11:40 Symposium 14 Indications and Outcomes of Curative Salvage Surgery		12:00~12:50 Luncheon Seminar 23 The Optimal Solution Varies by Country : What pharmacological therapies are best suited for EGFR mutation-positive lung cancer in the Japanese population?	13:00~13:30 Educational Lecture 15	13:30~14:00 Educational Lecture 16	14:00~14:30 Educational Lecture 17	14:30~15:00 Educational Lecture 18	15:05~16:05 Abstract Oral 50 Immunotherapy : Drug-Induced Lung Injury and irAE		
	Room 3 7F B Block Hall B7 (2)		8:30~11:30 Lung Cancer Screening Interpretation Seminar 2025				12:00~12:50 Luncheon Seminar 24 Perioperative immunotherapy for resectable NSCLC. Expectations from the AEGEAN regimen and other combinations.	13:00~14:30 Symposium : Academic Committee Program 2 Novel Therapeutic Target Candidate Molecules (SMARCA4, KRASG12X, B7-H3, MTAP, etc.)		14:35~15:05 Joint Committee on Database Management and Lung Cancer Registry Program Joint Committee Report on Lung Cancer Registration			
	Room 4 5F B Block Hall B5 (1)	7:40~8:20 Morning Seminar 5 FN Management in Lung Cancer	8:30~10:00 Workshop 10 Deep Discussion Series : Technical Aspects of Segmentectomy —What is Important?	10:10~11:40 Diversity Promotion Committee Program Work Style Reform		12:00~12:50 Luncheon Seminar 25 DLL3 Targeted Therapy in 3L SCLC : Translating Clinical Evidence into Practice.	13:00~14:30 Workshop 11 Surgical Indications for Metastatic Pulmonary Tumors in Modern Oncology		14:35~16:05 Video Session 4 Surgical Innovations 2				
	Room 5 5F B Block Hall B5 (2)	7:40~8:20 Morning Seminar 6	8:30~10:00 Chairman's Program 5 Delivering Palliative Care to Patients : Diagnosis and Treatment of Bone Metastases	10:10~11:40 Certification system Committee Program		12:00~12:50 Luncheon Seminar 26 A comprehensive Review of Amivantamab : Efficacy and Safety	13:00~15:20 Encore Abstract Session						
	Room 6 7F D Block Hall D7		8:30~9:30 Abstract Oral 51 Genomic Diagnosis and CGP 2	9:35~10:35 Abstract Oral 52 Immunotherapy : Biomarkers 2	11:00~11:40 Invited Lecture 9 Speaker : Haris Sair	12:00~12:50 Luncheon Seminar 27 Treatment Strategies for Driver-Positive Lung Cancer ~From Diagnosis to Therapy~	13:00~14:30 Sponsored Symposium 4 Supporting Lung Cancer Patients in Balancing Treatment and Work : Understanding Current Lung Cancer Treatments and Considering the Balance Between Work and Treatment	14:35~15:35 Abstract Oral 53 Team Medicine/ Nursing/ Rehabilitation : Perioperative					
	Room 7 5F D Block Hall D5	7:40~8:20 Morning Seminar 7	8:30~9:30 Medical Staff Symposium : Membership Committee Program 3 ACP	10:10~11:40 Early Career Support Committee Program 2 Share Your Experience Nationwide! Resident Case Presentation Award 2025		12:00~12:50 Luncheon Seminar 28 Impact of Angiogenesis Inhibitors on Lung Cancer Immunotherapy		14:10~16:10 Lung Cancer Care Seminar for Medical Students and Residents					
	Room 8 1F D Block Hall D1		8:30~9:30 Abstract Oral 54 Gene Mutation-Positive Lung Cancer (Other than EGFR)	9:35~10:35 Abstract Oral 55 Gene Mutation-Positive Lung Cancer (Basic Research)	10:40~11:40 Abstract Oral 56 Other	12:00~12:50 Luncheon Seminar 29 Ensuring the Best Treatment Journey for Every Lung Cancer Patient	13:00~14:00 Abstract Oral 57 Team Medicine/ Nursing/ Rehabilitation : Elderly and Other Patients	14:05~14:35 Abstract Oral 58 Advocacy					
	Room 9 5F G Block G502		8:30~9:30 Abstract Oral 59 Prognosis (Early-Stage Lung Cancer) 1	9:35~10:35 Abstract Oral 60 Prognosis (Early-Stage Lung Cancer) 2	10:40~11:40 Abstract Oral 61 Pathological Diagnosis	12:00~12:50 Luncheon Seminar 30 Perioperative Immunotherapy for Resectable Non-Small Cell Lung Cancer	13:00~14:00 Abstract Oral 62 Immunotherapy and Advanced Research for Lung Cancer	14:05~15:05 Abstract Oral 63 EGFR Gene Mutation-Positive Lung Cancer 2					
	Room 10 5F G Block G510		8:30~9:30 Abstract Oral 64 English Session 4 Driver Mutant Lung Cancer 2 Chairs : Tetsu Kobayashi Joseph Treat	9:35~10:35 Abstract Oral 65 English Session 5 Trials in Progress and Translational Research Chairs : Shinichi Sasaki Solange Peters	10:40~11:40 Abstract Oral 66 IO and Driver Mutant Lung Cancer Chairs : Takaaki Sasaki Geoffrey Liu	12:00~12:50 Luncheon Seminar 31 Staging of Lung Cancer : Focused on Imaging	13:00~14:00 Abstract Oral 67 Prognosis and Prognostic Factors (for Thymic Tumors) 1	14:05~15:05 Abstract Oral 68 Prognosis and Prognostic Factors (for Thymic Tumors) 2					
	PAP 4F G Block G409		P58 Biomarkers Pathology 3 P59 High-Risk P60 Rare Cases P62 Locally Advanced 2	P63 Surgical Techniques (for Thymic Tumors) 2 P64 Prognosis P65 Extended Surgery P66 SCLC 5 P67 Case Reports (EGFR and ALK)	P68 Diagnostics 5 P69 Non-Small Cell Lung Cancer Locally Advanced (Stage III) : Chemoradiotherapy P70 Non-Small Cell Lung Cancer Locally Advanced (Stage III) : Perioperative Treatment P71 Immunotherapy : Special Populations P72 Radiation Therapy, Case Reports, etc.	9:00~16:30 Patient Advocate Program (PAP)							
Poster venue B2F Hall E		8:00~9:30 Poster Mounting	9:30~10:40 Poster Viewing	10:40~11:40 Poster Presentation 5	11:40~13:00 Poster Viewing	13:00~14:00 Poster Presentation 6	14:00~15:40 Poster Viewing	15:40~16:10 Poster Removal					

- P73 Pathology 4
- P74 Locally Advanced 4
- P75 Other : Case Reports
- P76 Other : Surgery
- P77 Surgery : Other
- P78 Robotic and Thoracoscopic Surgery
- P79 Trial in Progress
- P80 Advocacy
- P81 Oligorecurrence and Salvage
- P82 Internal Medicine : Other
- P83 Team Medicine/Nursing/Rehabilitation : Nursing and Other Care
- P84 Immunotherapy : Combination Immunotherapy and Perioperative Immunotherapy
- P85 EGFR
- P86 Cytotoxic Anticancer Drugs